Xofigo patient reviews how to#

Here we review RWE studies investigating the efficacy and safety of 223Ra in mCRPC, as well as response marker development, imaging techniques, and current clinical practice recommendations. RWE studies lack the conventional restraints of clinical trials and can therefore help to build an understanding of how treatments may be best used in routine practice.

Xofigo patient reviews how to#

How to optimize 223Ra use, including how to integrate it into the mCRPC management pathway amongst other current LPTs (i.e., with respect to timing and concurrent, layered, or sequential use), is therefore of considerable interest. A large body of real-world evidence (RWE) for 223Ra has been published in the decade since the pivotal phase 3 ALSYMPCA study, a period during which the treatment landscape has continued to evolve. Despite being a life-prolonging therapy (LPT), 223Ra remains underutilized. Radium-223 dichloride ( 223Ra) is an α-emitter approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, but without visceral involvement. 9Carolina Urologic Research Center, Myrtle Beach, SC, United States.8Bayer HealthCare Pharmaceuticals, Whippany, NJ, United States.7Bayer Consumer Care, Basel, Switzerland.6Division of Urology, Institut de Recherche Clinique (IREC), Cliniques Universitaires Saint Luc, Brussels, Belgium.5Duke University School of Medicine, Durham, NC, United States.4Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.

3Department of Nuclear Medicine, University of Münster Medical Center, Münster, Germany.2Division of Hematology-Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA, United States.

Johnston Centre for Cancer Research, Queen’s University Belfast and Northern Ireland Cancer Centre, Belfast, United Kingdom George 5 Bertrand Tombal 6 Anja Schmall 7 Per Sandström 8 Frank Verholen 7 Neal Shore 9 McKay 2 Kambiz Rahbar 3 Karim Fizazi 4 Daniel J.